Biofluid Biomarkers of Amyotrophic Lateral Sclerosis

Holden, Cory; Steyn, Frederik J.; Henderson, R.D.; McCombe, Pam; Rogers, Mary‐Louise; Shyuan, Ngo

doi:10.1007/978-1-0716-1712-0_11

Cited by 2 publications

(2 citation statements)

References 261 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are generally advantageous over electrophysiological, neurophysiological, tissue analysis and imaging markers in that testing is often easier for the participant, may incur lower expense and allows for reproducible quantification. 2 , 9-11 Biofluid candidates are being increasingly tested alongside candidate treatments in adaptive platform trials, such as the HEALEY ALS Platform trial for ALS, 12 with the same protocol and a shared placebo group used across multiple treatments being tested.…”

Section: Introductionmentioning

confidence: 99%

Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations

Rogers,

Schultz,

Karnaros

et al. 2023

Brain Communications

Self Cite

View full text Add to dashboard Cite

Amyotrophic Lateral Sclerosis is a relentless neurodegenerative disease that is mostly fatal within 3-5 years and is diagnosed on evidence of progressive upper and lower motor neuron degeneration. Around 15% of those with Amyotrophic Lateral Sclerosis also have frontotemporal degeneration, and gene mutations account for ∼10%. Amyotrophic Lateral Sclerosis is a variable heterogenous disease, and it is becoming increasingly clear that numerous different disease processes culminate in the final degeneration of motor neurons. There is a profound need to clearly articulate and measure pathological process that occur. Such information is needed to tailor treatments to individuals with Amyotrophic Lateral Sclerosis according to an individuals’ pathological fingerprint. For new candidate therapies, there is also a need for methods to select patients according to expected treatment outcomes, and measure the success, or not, of treatments. Biomarkers are essential tools to fulfil these needs, and urine is a rich source for candidate biofluid biomarkers. This review will describe promising candidate urinary biomarkers of Amyotrophic Lateral Sclerosis and other possible urinary candidates in future areas of investigation as well as the limitations of urinary biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations

Rogers,

Schultz,

Karnaros

et al. 2023

Brain Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results also showed that APL and PVI peptides have a high probability of targeting DPP4. Increases in glucose metabolism is possible in ALS by a strategy that increases pyruvate availability and glucose-6-phosphate hydrogenase activity, with decreased consumption of alternative tricarboxylic acid cycle substrates in the cortex and increase in the level of ribose 5-phosphate and glucose-6-phosphate in the spinal cord of SOD1 G93A ALS mice [ 87 ]. The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are rapidly metabolized by DPP4 [ 88 ].…”

Section: Discussionmentioning

confidence: 99%

In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis

Fatoki

Chukwuejim

Udenigwe

et al. 2023

IJMS

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is regarded as a fatal neurodegenerative disease that is featured by progressive damage of the upper and lower motor neurons. To date, over 45 genes have been found to be connected with ALS pathology. The aim of this work was to computationally identify unique sets of protein hydrolysate peptides that could serve as therapeutic agents against ALS. Computational methods which include target prediction, protein-protein interaction, and peptide-protein molecular docking were used. The results showed that the network of critical ALS-associated genes consists of ATG16L2, SCFD1, VAC15, VEGFA, KEAP1, KIF5A, FIG4, TUBA4A, SIGMAR1, SETX, ANXA11, HNRNPL, NEK1, C9orf72, VCP, RPSA, ATP5B, and SOD1 together with predicted kinases such as AKT1, CDK4, DNAPK, MAPK14, and ERK2 in addition to transcription factors such as MYC, RELA, ZMIZ1, EGR1, TRIM28, and FOXA2. The identified molecular targets of the peptides that support multi-metabolic components in ALS pathogenesis include cyclooxygenase-2, angiotensin I-converting enzyme, dipeptidyl peptidase IV, X-linked inhibitor of apoptosis protein 3, and endothelin receptor ET-A. Overall, the results showed that AGL, APL, AVK, IIW, PVI, and VAY peptides are promising candidates for further study. Future work would be needed to validate the therapeutic properties of these hydrolysate peptides by in vitro and in vivo approaches.

show abstract

Biofluid Biomarkers of Amyotrophic Lateral Sclerosis

Cited by 2 publications

References 261 publications

Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations

Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations

In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About